Stocks · News reference
Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K Estimate
Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.88) by 2.27 percent. This is a 2.27 percent decrease over losses of $(0.88) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.